Bio-Rad Laboratories (BIO) | Stock Overview & Key Data
Bio-Rad Laboratories Performance Comparison
Stock Range
Today's Range
Low: $295.30
High: $306.02
on October 3, 2025
52 Week Range
Low: $211.43
High: $387.99
on June 3, 2025
on November 6, 2024
All-Time High: $832.70 on August 30, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$8.4B
EPS
11.09
P/E Ratio (TTM)
27.55
Forward P/E
26.22
P/B Ratio
1.16
PEG Ratio
-0.24
Div. Yield
N/A
ROE
4.59%
Beta
0.969
Debt to Equity
19.73
Financial Highlights
Profitability
Gross Margin
52.99%
Operating Margin
12.19%
Profit Margin
12.50%
Returns and Earnings
Return on Assets (TTM)
1.59%
Return on Equity (TTM)
4.59%
EBITDA
$463.0M
Net Income (TTM)
$319.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$91.19
Quarterly Revenue Growth (YoY)
2.10%
Quarterly Earnings Growth (YoY)
2.06%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Bio-Rad Laboratories BIO | 8.38B Mid-cap | 12.58% | 6.05% | 21.44% | 30.13% | -6.34% | -11.12% | -28.78% | -46.04% |
| Abbott Laboratories ABT | 234.39B Mega-cap | 0.78% | 1.82% | 0.11% | 2.25% | 18.64% | 19.49% | 32.22% | 22.75% |
| Boston Scientific BSX | 144.20B Large-cap | -0.88% | -9.50% | -6.71% | -1.20% | 8.88% | 15.12% | 144.77% | 136.56% |
| Bio-Rad BIO.B | 8.41B Mid-cap | 0.00% | 15.31% | 13.92% | 17.72% | -12.51% | -14.92% | -36.76% | -46.25% |
| Globus Medical GMED | 8.17B Mid-cap | 8.58% | 2.86% | 2.21% | -16.02% | -26.09% | -14.41% | 1.15% | 12.92% |
| Masimo MASI | 8.00B Mid-cap | 4.17% | 7.69% | -12.10% | -3.33% | -12.62% | 6.09% | 9.68% | -39.24% |
Ownership & Short Interest
Insider Ownership
16.24%
Institutional Ownership
89.63%
Shares Short
1M
Short Ratio
4.84
Short % of Shares Outstanding
5.73%
Average 10-Day Volume
215K
Average 90-Day Volume
238K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BIO's 52-week high and low?
- In the last 52 weeks, Bio-Rad Laboratories reached a high of $387.99 (on November 6, 2024) and a low of $211.43 (on June 3, 2025).
- What is the market cap and P/E ratio for BIO?
- Curious about Bio-Rad Laboratories's size and valuation? Its market capitalization stands at 8.38B. When it comes to valuation, the P/E ratio (trailing twelve months) is 27.55, and the forward P/E (looking ahead) is 26.22.
- Does BIO pay dividends? If so, what's the yield?
- As for dividends, Bio-Rad Laboratories isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Bio-Rad Laboratories's main competitors or similar companies to consider before investing?
When looking at Bio-Rad Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT234.39B Healthcare Medical Devices 19.49% 32.22% Boston Scientific
BSX144.20B Healthcare Medical Devices 15.12% 144.77% Bio-Rad
BIO.B8.41B Healthcare Medical Devices -14.92% -36.76% Globus Medical
GMED8.17B Healthcare Medical Devices -14.41% 1.15% Masimo
MASI8.00B Healthcare Medical Devices 6.09% 9.68% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bio-Rad Laboratories Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Bio-Rad Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 4.59%, the Debt to Equity ratio from the most recent quarter is 19.73, and its Gross Profit Margin stands at 52.99%.
- What is the recent revenue and earnings growth for BIO?
- Looking at Bio-Rad Laboratories's growth, its revenue over the trailing twelve months (TTM) was $3B. Compared to the same quarter last year (YoY), quarterly revenue grew by 2.10%, and quarterly earnings saw a YoY growth of 2.06%.
- How much of BIO stock is held by insiders and institutions?
- Wondering who owns Bio-Rad Laboratories stock? Company insiders (like executives and directors) hold about 16.24% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 89.63%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.